行业背景
Repare Therapeutics Inc [RPTX]
最后更新 28 Jan 2026 @ 16:00 (Exchange is open)
最新： $2.65
0.00%
2.45 (↓)
GaG Algo Score™
v1.0
短期
2.45 (↓)
中期
4.41 (↓)
长期
4.17 (↓)
线图
枢轴数据
枢轴统计
枢轴数据不足，无法统计。
下一枢轴预测 最新： $2.65
无法基于可用数据生成预测。
Repare Therapeutics Inc flat yesterday.
Repare Therapeutics Inc (RPTX) stock price finished at the same level as the previous day on Wednesday after the stock unchanged $0 (0.00%) from the previous session on extremely light volume. The stock held up slightly better than the falling NASDAQ (-0.47% down). Yesterday's trading volume was 0 shares, worth about $0.00. This represents 1.22M shares less than the day before. Volume was below the 10-day average of 998 815 shares.
Repare Therapeutics Inc signals
The last upturn is pushing the stock into overbought territory (RSI above 70) with a current RSI of 73.24, which traditionally suggests the stock may be overvalued in the short term. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (36.7%), medium- (36.7%), and long-term (36.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Repare Therapeutics Inc Support & Resistance Levels
The stock is trading above the closest support level at $2.55. approximately $0.100 (3.77%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s12.55 -
Repare Therapeutics Inc Evaluation
- 短期 评分: 2.45
- 中期 评分: 4.41
- 长期 评分: 4.17
内部人流向
GetAGraph InsiderPower
交易
46
买入力度
1.44M
卖出力度
5.70M
可靠度
97/100
买入 / 卖出
0.25
历史相关
0.27
最新信号
Sell 2026-01-28
Officer 33
Director 8
Executive 3
Major holder 2
2026-01-28
Bvf Partners L P/il Major holder
Sell 548 938
2026-01-28
Bvf Partners L P/il Major holder
Sell 548 938
2026-01-28
Schafer Carol Director
Sell 37 941
2026-01-28
Schafer Carol Director
Sell 8 000
2026-01-28
Rhoads Ann D Director
Sell 4 000
2026-01-28
Civik Thomas Director
Sell 7 500
关系图
相关性概览
Positioning pressure
Short interest pressure
Short interest
1.02%
Of outstanding shares
Short float
1.26%
Of tradable float
Days to cover
1.000
Short interest divided by average volume
Squeeze probability
5.00%
+125.33% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2026-01-15Earnings quality
Earnings history
Reported quarters
12
EPS beats
9
EPS misses
3
Avg. surprise
184.22%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q1/2025 | 2025-05-13 | $-0.630 | $-0.650 | 3.08% | 2.50M |
| Q4/2024 | 2025-03-03 | $-0.670 | $-0.770 | 12.99% | -53.48M |
| Q3/2024 | 2024-11-07 | $-0.810 | $-0.830 | 2.41% | - |
| Q2/2024 | 2024-08-06 | $-0.820 | $-0.850 | 3.53% | 1.07M |
| Q1/2024 | 2024-05-07 | $0.300 | $0.0157 | 1 809.61% | 52.40M |
| Q4/2023 | 2024-02-28 | $-0.670 | $-0.560 | -19.64% | 13.05M |
| Q3/2023 | 2023-11-09 | $-0.450 | $-0.860 | 47.67% | 2.16M |
| Q2/2023 | 2023-08-09 | $-0.280 | $-0.830 | 66.27% | 30.25M |
Analyst view
Analyst targets
Consensus
$16.00
Median
$15.00
Low
$3.00
High
$30.00
News flow
Latest company news
Market coverage
defenseworld.net Repare Therapeutics (NASDAQ:RPTX) Trading Up 0.8% – What’s Next? Feb 20, 2026 businesswire.com Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. Jan 16, 2026 defenseworld.net Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% – Here’s Why Jan 15, 2026 defenseworld.net Repare Therapeutics Target of Unusually Large Options Trading (NASDAQ:RPTX) Dec 25, 2025Company releases
Company context
Company profile
交易所：
NASDAQ
板块：
Healthcare
行业：
Biotechnology
Currency
USD
Repare Therapeutics Inc a clinicalstage precision oncology company discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States The company uses its SNIPRx a proprietary genomewide and CRISPRenabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability including DNA damage repair Its lead product candidate is RP3500 an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repairrelated genomic alterations It is also developing RP6306 which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification and Polymerase Theta program a SL target associated with BRCA mutations and other genomic alterations The company was incorporated in 2016 and is headquartered in Montreal Canada
Navigation